A Cost Story, Not a Sales Story
May & Baker's nine-month result is a study in operating discipline. Sales grew less than 5% to ₦30.97 billion — modest even by the standards of a difficult consumer market — yet the amount it cost the drugmaker to produce what it sold fell by 11.1% to ₦17.26 billion. Producing more cheaply while selling slightly more is the most powerful combination in manufacturing accounts, and it shows in the gross line: gross profit jumped 35.6% to ₦13.71 billion, and gross margin expanded by ten percentage points to 44.3%.
The improvement carried straight down the account. Operating profit rose 66.3% to ₦8.45 billion, and pre-tax profit climbed 81.5% to ₦8.92 billion — growing faster than operating profit, which indicates a lighter finance burden below the operating line as well. The third quarter alone contributed ₦2.69 billion of net profit on revenue of ₦11.69 billion, according to the filing, making it the strongest quarter of the three.
The Tax Line Took Its Share
Success attracted a bigger tax bill. Income tax rose 92.8% to ₦3.03 billion, faster than pre-tax profit itself, so the bottom line grew a touch more slowly than the pre-tax result. Shareholders still kept ₦5.89 billion — a 76.2% increase that few listed manufacturers will match this season — and retained earnings helped lift equity to ₦18.54 billion against total assets of ₦34.46 billion.
What Investors Watch Next
The sustainability question is whether the cost gains are structural or one-off. A ten-point margin jump in nine months usually reflects a mix of cheaper inputs, product mix and tighter factory economics; only part of that mix is guaranteed to repeat. Investors will look to the full-year results for two things: whether gross margin holds near the mid-40s, and whether revenue growth can accelerate toward double digits so that future profit growth does not depend entirely on squeezing costs. On the evidence of the first nine months, May & Baker has bought itself room to do both.
